ExAdEx NAM organoids to reduce animal experimentation
Organoid models developed by ExAdEx-Innov and collaborators presented at the 3R LÄND CONFERENCE 2024 in Tübingen (Germany) Latest work from ExAdEx-Innov team on clinically relevant
Latest work on adipose tissue and obesity performed by our researchers and collaborators has been selected for a poster presentation at the 31st European Congress on Obesity (ECO) 2024 in Venice, Italy.
Poster presentation will take place during the G-communications sessions on May 13th and 14th.
The results shown during ECO 2024 open important perspectives for the development of a clinically-relevant human adipose tissue model for obesity that can thus be used to accelerate the development of molecules counteracting pathological remodelling of adipose tissue as observed in obesity and to identify novel molecules converting the adipose tissue of donors with obesity into a tissue capable of energy expenditure.
The work presented at ECO 2024 has been performed in collaboration with Université Côte d’Azur, the Digestive Surgery Department of Centre Hospitalier Universitaire (CHU) de Nice directed by Professor Antonio Iannelli and has also received financial support by a Bourse French Tech Emergence by BpiFrance. Based on the results generated, ExAdEx-Innov has recently initiated a 3-year PhD program co-funded by ANRT, Agence Nationale de la Recherche et de la Technologie (CIFRE Thesis project) aimed at developing applications of ExAdEx technology for the pharmaceutical industry.
31st European Congress on Obesity
WHERE: Venice (Italy)
WHEN: May 13th and 14th 2024
ABSTRACT TITLE: Donor-derived vascularized organoids modelling inflammation, fibrosis and beiging therapeuticaleffects of human adipose tissue
For more information about the program, check the congress website here
#ECO2024
Organoid models developed by ExAdEx-Innov and collaborators presented at the 3R LÄND CONFERENCE 2024 in Tübingen (Germany) Latest work from ExAdEx-Innov team on clinically relevant
ExAdEx-Innov has received approval from the French Ministry of Research as a service provider eligible to French Research Tax Credit (Agrément CIR, Crédit Impôt Recherche)
ExAdEx-Innov announces the signature of a licence agreement with CNRS Innovation on human stem cell model to enlarge R&D platform tools from cells to tissue
Copyright © 2022 ExAdEx-Innov All rights reserved
KOL on adipose tissue biology.
Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice).
Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program).
Co-inventor of 5 patents
Expert in clinical applications of adipose tissue.
Plastic Reconstructive and Aesthetic Surgeon in Nice.
Member of the Medical Council of Alpes Maritimes region.
Expert for the French National Regulatory Agency ANSM for medical devices.
Certified by French Health Autority HAS (2020-2024).
PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.
Expert in cell therapy and immunology.
Senior Lecturer (Maitre de conférences).
Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).
Director of « Micoralis » research team at Université Côte d’Azur (Nice).
Founder and CEO of the biotech company Biointerférence (2003-2006).
Co-inventor of 5 patents.
Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.
With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov.
In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille).
He is co-inventor of the 2 company’s patent families.
Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue.
Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.
With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years.
He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.
Main areas of expertise: Biotech Startup Business Development; Project management